BULDINI, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.303
AS - Asia 5.344
EU - Europa 2.606
SA - Sud America 979
AF - Africa 912
Continente sconosciuto - Info sul continente non disponibili 200
OC - Oceania 79
Totale 19.423
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.680
SG - Singapore 1.724
CN - Cina 889
VN - Vietnam 722
IT - Italia 644
BR - Brasile 601
HK - Hong Kong 512
BD - Bangladesh 299
DE - Germania 248
FR - Francia 191
FI - Finlandia 184
IN - India 153
CA - Canada 135
GB - Regno Unito 121
PL - Polonia 116
RU - Federazione Russa 102
AR - Argentina 93
SE - Svezia 92
IQ - Iraq 89
NL - Olanda 85
IE - Irlanda 83
TR - Turchia 75
MX - Messico 69
JP - Giappone 66
AT - Austria 64
ZA - Sudafrica 59
CO - Colombia 58
UA - Ucraina 55
PH - Filippine 49
SA - Arabia Saudita 48
CZ - Repubblica Ceca 47
PK - Pakistan 44
EC - Ecuador 40
JO - Giordania 40
UZ - Uzbekistan 40
ES - Italia 39
ID - Indonesia 39
VE - Venezuela 38
KE - Kenya 37
KR - Corea 35
DO - Repubblica Dominicana 34
JM - Giamaica 34
PR - Porto Rico 34
MA - Marocco 33
PT - Portogallo 33
YT - Mayotte 33
PE - Perù 32
BE - Belgio 31
CI - Costa d'Avorio 31
CR - Costa Rica 31
EG - Egitto 30
MY - Malesia 30
RO - Romania 30
AL - Albania 29
HN - Honduras 29
AO - Angola 28
DK - Danimarca 28
DZ - Algeria 28
PY - Paraguay 28
BJ - Benin 27
CY - Cipro 27
MK - Macedonia 27
ML - Mali 27
BO - Bolivia 26
CH - Svizzera 26
GT - Guatemala 26
MZ - Mozambico 26
NP - Nepal 26
SN - Senegal 26
AZ - Azerbaigian 25
CU - Cuba 25
NG - Nigeria 25
TT - Trinidad e Tobago 25
UY - Uruguay 25
ET - Etiopia 24
LU - Lussemburgo 24
PA - Panama 24
TH - Thailandia 24
TJ - Tagikistan 24
TW - Taiwan 24
AM - Armenia 23
EE - Estonia 23
KG - Kirghizistan 23
YE - Yemen 23
GH - Ghana 22
HU - Ungheria 22
IL - Israele 22
LA - Repubblica Popolare Democratica del Laos 22
MD - Moldavia 22
ME - Montenegro 22
MN - Mongolia 22
RS - Serbia 22
TN - Tunisia 22
ZM - Zambia 22
AE - Emirati Arabi Uniti 21
GE - Georgia 21
KZ - Kazakistan 21
UG - Uganda 21
BB - Barbados 20
BW - Botswana 20
Totale 18.260
Salva come PNG Salva come JPEG
Città #
Ashburn 1.239
Singapore 1.032
San Jose 991
Fairfield 846
Woodbridge 495
Hong Kong 467
Chandler 379
Ann Arbor 360
Houston 358
Cambridge 308
Seattle 269
Wilmington 218
Ho Chi Minh City 210
Beijing 193
Santa Clara 186
Hanoi 179
Los Angeles 166
Boardman 145
San Diego 118
Council Bluffs 111
Jacksonville 97
Lauterbourg 97
Helsinki 96
New York 89
Princeton 86
Munich 82
Dublin 78
Des Moines 71
Medford 64
Milan 62
Bytom 56
Orem 55
Rome 55
São Paulo 54
Padova 53
Guangzhou 50
Chicago 49
Da Nang 47
Warsaw 47
Tokyo 45
Buffalo 41
London 40
Montreal 40
Amman 39
Padua 38
Frankfurt am Main 37
Turku 36
Baghdad 35
Tashkent 35
Dallas 34
The Dalles 34
Haiphong 32
Nairobi 32
Washington 32
Hefei 31
Roxbury 31
Stockholm 30
Vienna 30
Abidjan 29
Johannesburg 29
Nanjing 28
Nuremberg 28
Rio de Janeiro 27
Cotonou 26
Dakar 25
Mexico City 25
San José 25
Baku 24
Bamako 24
Dong Ket 24
Atlanta 23
Denver 23
Lusaka 22
Naples 22
Panama City 22
Ulan Bator 22
Brooklyn 21
Dushanbe 21
Luanda 21
Vientiane 21
Chennai 20
Podgorica 20
Addis Ababa 19
Bishkek 19
Havana 19
Kampala 19
Maputo 19
Montevideo 19
Santo Domingo 19
Seoul 19
Bridgetown 18
Brno 18
Buenos Aires 18
Gaborone 18
Kingston 18
Managua 18
Phoenix 18
Shanghai 18
Yerevan 18
Accra 17
Totale 11.133
Salva come PNG Salva come JPEG
Nome #
Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients 434
A Novel t(8;14)(q24;q11) Rearranged Human Cell Line as a Model for Mechanistic and Drug Discovery Studies of NOTCH1-Independent Human T-Cell Leukemia 297
Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia 287
Thioridazine requires calcium influx to induce MLL-AF6-rearranged AML cell death 286
Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML. 285
Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group 282
An extensive quality control and quality assurance (QC/QA) program significantly improves inter-laboratory concordance rates of flow-cytometric minimal residual disease assessment in acute lymphoblastic leukemia: An I-BFM-FLOW-network report 281
Long-term proliferation of immature hypoxia-dependent JMML cells supported by a 3D in vitro system 273
mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells 270
Biologic and clinical analysis of childhood gamma delta T-ALL identifies LMO2/STAG2 rearrangements as extremely high-risk 267
Cerebrospinal fluid analysis by 8-color flow cytometry in children with acute lymphoblastic leukemia 265
Low-Blood Lymphocyte Number and Lymphocyte Decline as Key Factors in COPD Outcomes: A Longitudinal Cohort Study 255
Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL 254
The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL 254
Prognostic Role of Minimal Disseminated Disease and NOTCH1/FBXW7 Mutational Status in Children with Lymphoblastic Lymphoma: The AIEOP Experience 250
CD56, HLA-DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3-GLIS2 fusion transcript 245
Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia 240
Comparison of MRD detection by RQ-PCR and droplet digital PCRin pediatric Acute Lymphoblastic Leukemia before Hematopoietic Stem Cell Transplantation 240
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia 234
Low PKCα expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome. 233
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. 222
The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols 220
Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols 214
Next-generation sequencing of PTEN mutations for monitoring minimal residual disease in T-cell acute lymphoblastic leukemia 213
Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus 212
Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia 208
Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion 208
Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience 207
Aspergillus flavus Disseminated Infection in Paediatric Acute Lymphoblastic Leukaemia: A Case Report 207
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 204
Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol 204
CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment 202
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-Lineage acute lymphoblastic leukemia. 201
Moving forward in target antigen discovery for immunotherapy in acute myeloid leukemia 200
Advanced Pediatric Myelodysplastic Syndromes. Can Immunophenotypic Characterization of Blasts Cells be a Diagnostic and Prognostic Tool? 199
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis 199
Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in children 198
Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. 197
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study 196
A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia 196
Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration 196
Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high???risk first relapse B???cell precursor acute lymphoblastic leukemia 195
CD72 is a pan-tumor antigen associated to pediatric acute leukemia 195
MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study 192
Unrelated donor vs HLA-haploidentical a/b T-cell– and B-cell–depleted HSCT in children with acute leukemia 190
International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia 188
CD371 cell surface expression: A unique feature of DUX4-rearranged acute lymphoblastic leukemia 188
SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia 185
Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies 184
FCM marker importance for MRD assessment in T-Cell Acute Lymphoblastic Leukemia: An AIEOP-BFM-ALL-FLOW Study Group Report 182
Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow 181
IDENTIFICATION OF IMMUNOPHENOTYPIC SIGNATURES BY CLUSTERING ANALYSIS IN PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 180
Flow cytometry application in hematological malignancies of childhood 178
Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. 175
NUP214-ABL1 fusion in childhood T-ALL 175
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. 174
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols 174
The genetic basis and cell of origin of mixed phenotype acute leukaemia 167
Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease 165
Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation 164
FLT3‐ITD in Children with Early T‐cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD) 163
Health technology assessment–based approach to flow cytometric immunophenotyping of acute leukemias: a literature classification 163
Immunophenotype segnature as a tool to define prognostic subgroups in childhood acute myeloid leucemia. 162
Acute Lymphoid Leukaemias (ALL) and Minimal Residual Disease in ALL 156
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 155
Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia 154
Diagnostic challenges in acute monoblastic/monocytic leukemia in children 153
Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia 151
Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial 150
Flow diagnostics essential code: a simple and brief format for the summary of leukemia phenotyping. 146
Trisomy 7 and deletion of the 9p21 locus as novel acquired abnormalities in a case of pediatric biphenotypic acute leukemia. 145
La sindrome di Dandy Walker: follow-up in due differenti casistiche 142
AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia 142
MLL partner genes specify distinct biological and clinical signatures in pediatric acute myeloidleukemia. An AIEOP study. 141
Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients 141
Time point-dependent concordance of flow cytometry and RQ-PCR inminimal residual disease detection in childhood acute lymphoblasticleukemia. 140
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group 139
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia 138
Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials 137
Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000 137
TCRαβ/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis 136
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study 136
Flow-cytometric MRD detection in pediatric T-ALL: a multicenter AIEOP-BFM consensus-based guided standardized approach 135
Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B cell precursor acute lymphoblastic leukemia 135
Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing 135
Spinal cord injury without radiographic abnormalities 134
Leukemia blast cell identification 133
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: Revisited in AIEOP-BFM protocol 133
Childhood cancer in Italy: background, goals, and achievements of the Italian Paediatric Hematology Oncology Association (AIEOP) 132
FLT3-ITD As a Target for Minimal Residual Disease Monitoring in Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia 131
Symmetrical thalamic calcifications in a monozygotic twin: case report and literature review 129
Favorable Outcome of Children with Acute Megakaryoblastic Leukemia Treated with the AIEOP AML 2002/01 Protocol 129
Symmetrical thalamic calcifications in a monozygotic twin: case report and literature review 127
Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement 127
New methodologic approaches for immunophenotyping acute leukemias 123
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment 119
SPECKLE TRACKING ECHOCARDIOGRAPHY IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY STUDY 117
Donor multipotent mesencymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation. 116
Identification Of Low Risk Group In Infants With Acute Lymphoblastic Leukemia By Flow Cytometric Minimal Residual Disease Measurement At Day 15 Of Interfant-99 and Interfant-06 Protocols Treatment 112
Near-tetraploid T-cell acute lymphoblastic leukaemia in childhood: Results of the AIEOP-BFM ALL studies 110
Totale 18.671
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.025
article - articoli 52.570
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 467
Totale 108.062
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.027 0 78 140 59 44 50 87 122 83 38 130 196
2022/2023823 149 87 23 87 131 96 9 64 98 11 43 25
2023/2024713 27 67 86 53 54 155 62 53 21 17 51 67
2024/20252.555 20 144 106 92 274 45 185 280 234 100 427 648
2025/202610.456 485 805 1.352 1.693 847 442 1.262 763 1.183 548 611 465
2026/2027750 514 236 0 0 0 0 0 0 0 0 0 0
Totale 19.423